Sunitinib shown to improve disease-free survival in people with kidney cancer

Results frounknownm the S-TRAC study were presented at the European Society of Medical Oncology. (ESMO) congress in Copenhagen this week. The results show that sunitinib  improved disease-free survival in patients with localised kidney cancer  that had been surgically removed; a group considered high-risk for relapse. Read more